Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Accumulated Expenses (2022 - 2024)

Universe Pharmaceuticals (UPC) has disclosed Accumulated Expenses for 3 consecutive years, with $49.5 million as the latest value for Q3 2024.

  • Quarterly Accumulated Expenses rose 1724.48% to $49.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $49.5 million through Sep 2024, up 1724.48% year-over-year, with the annual reading at $49.5 million for FY2024, 1724.48% up from the prior year.
  • Accumulated Expenses hit $49.5 million in Q3 2024 for Universe Pharmaceuticals, up from $2.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $49.5 million in Q3 2024 to a low of $2.5 million in Q3 2022.
  • Historically, Accumulated Expenses has averaged $18.2 million across 3 years, with a median of $2.7 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: rose 6.79% in 2023 and later surged 1724.48% in 2024.
  • Year by year, Accumulated Expenses stood at $2.5 million in 2022, then increased by 6.79% to $2.7 million in 2023, then soared by 1724.48% to $49.5 million in 2024.
  • Business Quant data shows Accumulated Expenses for UPC at $49.5 million in Q3 2024, $2.7 million in Q3 2023, and $2.5 million in Q3 2022.